SOD2 and myeloid sarcoma: Results revealed that individuals with MS exhibited significantly lower superoxide dismutase (SOD) activity (including MnSOD and CuZnSOD), higher total antioxidant capacity (TAC), and reduced thiol group concentrations compared to non-MS individuals.